Company Information
Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 ADC at the 2023 AACR Annual Meeting
Peak Bio, Inc introduces a novel immunostimulatory ADC payload targeting RNA splicing and demonstrates tumoricidal properties of a proof-of concept Her2 ADC at the 2021 AACR annual meeting
April 19, 2023
Download PosterPeak Bio, Inc introduces a novel immunostimulatory ADC payload targeting RNA splicing and demonstrates tumoricidal properties of a proof-of concept Her2 ADC at the 2021 AACR annual meeting
April 10, 2021
Download Poster